BioSpace News Archive

Leaders from Kaiser Permanente’s The Permanente Federation, Mayo Clinic, Salesforce, Verily, and Google will share their insights on the best uses of artificial intelligence (AI) in health care during a free Permanente Live webinar on September 26, 2022.

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177.

Propath UK, Europe’s leading CRO for spatial biology, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking spatial biology insights from pathology data, announce their collaboration to develop and validate a 30-plex immunofluorescence (IF) panel focused on protein targets relevant to immuno-oncology.

Alliance Pharma, a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing on board a new Chief Operating Officer, Chief Commercial Officer, Chief Financial Officer, and Chief People Officer.

VBI Vaccines Inc. today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France.

Sonnet BioTherapeutics Holdings, Inc., announced today that initial safety has been formally reviewed in both Phase 1 clinical trials of SON-1010(IL12-FHAB) in adults and that dose escalation is continuing.

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical & Health Informatics (MEI) Lab has delivered a paper proposing a system design for optimizing drug infusions for acute heart failure and has begun testing out the design at Japan’s National Cerebral and Cardiovascular Center (NCVC).

Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference.